Verastem, Inc.
Verastem (Nasdaq: VSTM) is a biopharmaceutical company developing and commercializing medicines for RAS/MAPK pathway-driven cancers. Its marketed U.S. product, AVMAPKI FAKZYNJA CO-PACK, combines avutometinib and defactinib and is approved for adults with KRAS-mutated recurrent low-grade serous ovarian cancer who have… From the company’s description.
Over the twelve months to Sep 30, 2026, Verastem, Inc. reported revenue of $100.30M, up 649.7% from a year earlier, and a net loss of $178.90M. Its operating margin was −193.7%, and operations used $159.57M in cash. In fiscal 2025, it reported revenue of $30.91M, up 209.1% from fiscal 2024, and a net loss of $209.47M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Verastem, Inc. does
In the company’s own words
Verastem (Nasdaq: VSTM) is a biopharmaceutical company developing and commercializing medicines for RAS/MAPK pathway-driven cancers. Its marketed U.S. product, AVMAPKI FAKZYNJA CO-PACK, combines avutometinib and defactinib and is approved for adults with KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy. The company’s pipeline includes VS-7375, an oral KRAS G12D inhibitor in clinical development for pancreatic, lung, colorectal and other solid tumors, as well as programs evaluating avutometinib and defactinib in combination with chemotherapy or other cancer medicines. Verastem focuses on small-molecule therapies that target RAS directly, inhibit RAF/MEK signaling downstream, or address FAK-mediated resistance. Its commercial operations serve patients and healthcare providers in the United States, while its research and clinical programs address additional cancer indications and markets. In 2025, the company recorded $30.9 million in net product revenue during the first seven months of the product’s commercial launch. Its website is www.verastem.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- NEEDHAM, MA
- Fiscal year end
- December
- CIK
- 1526119
- SIC
- 2834
Financial performance, year by year
Fiscal 2012–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Verastem, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Verastem, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Verastem, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Verastem, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Verastem, Inc.'s last four quarterly filings that the numbers alone won't show?”